{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:09:51Z","timestamp":1790359791563,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital","award":["DOH96-TD-B-111-001"],"award-info":[{"award-number":["DOH96-TD-B-111-001"]}]},{"name":"NSC 97-2628-B-002-004-MY3","award":["NSC 98-3112-B-002-038"],"award-info":[{"award-number":["NSC 98-3112-B-002-038"]}]},{"name":"American Society of Clinical Oncology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.jhep.2010.01.035","type":"journal-article","created":{"date-parts":[[2010,3,31]],"date-time":"2010-03-31T08:50:47Z","timestamp":1270025447000},"page":"126-131","source":"Crossref","is-referenced-by-count":102,"title":["Phase II study of combining sorafenib with metronomic tegafur\/uracil for advanced hepatocellular carcinoma"],"prefix":"10.1016","volume":"53","author":[{"given":"Chih-Hung","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Chun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Zhe","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yea-Hui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2010.01.035_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia\u2013Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2010.01.035_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cct.2009.08.002","article-title":"Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design","volume":"31","author":"Hsu","year":"2010","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jhep.2010.01.035_bib3","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2010.01.035_bib4","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2010.01.035_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2010.01.035_bib6","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2010.01.035_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","article-title":"Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma","volume":"99","author":"Furuse","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jhep.2010.01.035_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cncr.24029","article-title":"Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response","volume":"115","author":"Yau","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2010.01.035_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1634\/theoncologist.2008-0191","article-title":"Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis","volume":"14","author":"Pinter","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2010.01.035_bib10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/MCG.0b013e31818ddfc6","article-title":"Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis","volume":"43","author":"W\u00f6rns","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2010.01.035_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2010.01.035_bib12","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2005-04-1422","article-title":"Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity","volume":"106","author":"Shaked","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2010.01.035_bib13","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2010.01.035_bib14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/annonc\/mdj066","article-title":"Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects","volume":"17","author":"Colleoni","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2010.01.035_bib15","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","article-title":"Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer","volume":"26","author":"Dellapasqua","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2010.01.035_bib16","first-page":"13","article-title":"UFT: mechanism of drug action","volume":"14","author":"Kohne","year":"2000","journal-title":"Oncology (Huntingt)"},{"key":"10.1016\/j.jhep.2010.01.035_bib17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/00001813-200310000-00003","article-title":"Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer","volume":"14","author":"Schmoll","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jhep.2010.01.035_bib18","doi-asserted-by":"crossref","unstructured":"Tokyo Liver Cancer Chemotherapy Study Group. Phase II study of co-administration of uracil and tegafur (UFT) in hepatocellular carcinoma. Japan J Clin Oncol 1985;15:559\u201362.","DOI":"10.1093\/oxfordjournals.jjco.a039083"},{"key":"10.1016\/j.jhep.2010.01.035_bib19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1440-1746.2001.02352.x","article-title":"Improved survival with oral administration of enteric-coated tegafur\/uracil for advanced stage IV-A hepatocellular carcinoma","volume":"16","author":"Ishikawa","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2010.01.035_bib20","first-page":"2185","article-title":"UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice","volume":"5","author":"Yonekura","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2010.01.035_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1014059528046","article-title":"Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor","volume":"4","author":"Basaki","year":"2001","journal-title":"Angiogenesis"},{"key":"10.1016\/j.jhep.2010.01.035_bib22","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-05-4411","article-title":"Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy","volume":"66","author":"Munoz","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2010.01.035_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2010.01.035_bib24","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa032792","article-title":"A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung","volume":"350","author":"Kato","year":"2004","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jhep.2010.01.035_bib25","first-page":"1037","article-title":"Sample size requirements for evaluating a conservative therapy","volume":"62","author":"Makuch","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.jhep.2010.01.035_bib26","doi-asserted-by":"crossref","unstructured":"A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751\u20135.","DOI":"10.1002\/hep.510280322"},{"key":"10.1016\/j.jhep.2010.01.035_bib27","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/sj.bjc.6602474","article-title":"Can a rational design for metronomic chemotherapy dosing be devised?","volume":"92","author":"Maraveyas","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2010.01.035_bib28","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrc1971","article-title":"The multifaceted circulating endothelial cell in cancer: towards marker and target identification","volume":"6","author":"Bertolini","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2010.01.035_bib29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.drudis.2007.08.011","article-title":"Molecular and cellular biomarkers for angiogenesis in clinical oncology","volume":"12","author":"Bertolini","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jhep.2010.01.035_bib30","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/annonc\/mdn030","article-title":"Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials","volume":"19","author":"Collette","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2010.01.035_bib31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.bjc.6605580","article-title":"Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma","volume":"102","author":"Hsu","year":"2010","journal-title":"Br J Cancer"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781000187X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781000187X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T12:43:02Z","timestamp":1711370582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882781000187X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S016882781000187X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2010.01.035","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}